Amendment to the Second Point and Its Appendix of the ‘Documents to Be Submitted for Case-by-Case Review of the Use of Exosomes Derived from Human Cells in Cosmetics’, Effective from the Date of Issuance

Members
twMedium riskReview the revised appendix to ensure compliance with the new document requirements for case-by-case review applications.
August 25, 2026

Original source

Regulation / act

修正「申請源自人體細胞之外泌體使用於化粧品之個案審查應檢送文件」第二點附表,並自即日生效。

Official date
2026-02-02
Unlock the official file

Business Impact stays free. Paid plans unlock the original source, official text, and Regulatory Details — plus Workbench and Verify credits.

Business Impact

Quick prioritisation for leadership

The Taiwan FDA has amended the required documents for case-by-case review of exosomes derived from human cells in cosmetics, effective immediately. Companies submitting such applications must follow the revised document requirements, including the updated appendix to the second point.

Scroll to Top